Non-regulatory press release

Prostatype Genomics AB announces outcome of TO 2

On March 30, 2023, the exercise period for Prostatype Genomics AB's ("Prostatype Genomics" or the "Company") warrants of series TO 2 ended. A total of 2,622 warrants of series TO 2 have been exercised, corresponding to SEK 7,603.80.

During the period from the 9th of March until the 30th of March 2023, holders of warrants of series TO 2 had the right to subscribe for shares with the support of warrants. One (1) warrant of series TO 2 gave the holder the right to subscribe for one (1) new share in Prostatype Genomics at a subscription price set at SEK 2.90. A total of 2,622 warrants of series TO 2 have been exercised, corresponding to a subscription of SEK 7,603.80. The exercise entails a dilution of 0.01 percent. Conversion from interim shares to ordinary shares is expected to take place around the 19th of April 2023 and ordinary shares are expected to be visible on each subscriber's account approximately two banking days thereafter.

After registration, the number of shares in the Company will amount to 22,862,119 shares and the share capital will amount to SEK 1,371,727.14.

For further information about TO 2, please contact
Sedermera Corporate Finance AB
Phone: +46 (0) 40 615 14 10

Nordic Issuing AB
Phone: +46 (0) 40 632 00 20

For further information about Prostatype Genomics, please contact
Nicklas Rosendal

Certified Advisor
Svensk Kapitalmarknadsgranskning AB
Phone: +46 (0) 11-32 30 732

Prostatype® is a genetic test that is available to patients and treating urologists as a supplementary decision basis for the question of treatment or not treatment of prostate cancer. The test is developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.